Ke Jiang, Jing Mou
Department of Neurology, East People's Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Department of Cardiology, Xuzhou City Center Hospital, Xuzhou, Jiangsu 221009, P.R. China.
Biomed Rep. 2016 Aug;5(2):155-158. doi: 10.3892/br.2016.692. Epub 2016 May 26.
The aim of the study was to investigate the clinical effect of urinary kallidinogenase combined with edaravone in the treatment of massive cerebral infarction. A total of 58 patients with massive cerebral infarction were admitted to hospital between January 2013 and January 2014. There were 34 male and 24 female patients. The patients were randomly divided into the observation and control groups (n=29 cases per group). The patients in the control group received edaravone treatment, while patients in the observation group were treated with urinary kallidinogenase and edaravone. The clinical effects of the two groups were then compared. The results showed that the National Institutes of Health Stroke Scale score and serum C-reactive protein level of the patients in the two groups were significantly decreased following treatment. The decreased degree in the observation group was significantly smaller than that in the control group. The difference was statistically significant [(11.03±3.75) vs. (16.58±7.43) scores, P<0.05; (9.88±4.82) vs. (11.98±4.69) mmol/l, P<0.05]. The serum levels of vascular endothelial growth factor were significantly increased in patients of the two groups after treatment. The increased degree in the observation group was significantly higher than that in the control group. The difference was statistically significant [(268.51±77.34) vs. (188.82±57.33) ng/l, P<0.05]. The total effective rate of the observation group was significantly higher than that of the control group and the difference was statistically significant (89.66 vs. 62.07%, P<0.05). In conclusion, urinary kallidinogenase combined with edaravone treatment has a certain clinical curative effect on massive cerebral infarction.
本研究旨在探讨尿激肽原酶联合依达拉奉治疗大面积脑梗死的临床疗效。2013年1月至2014年1月共收治58例大面积脑梗死患者，其中男性34例，女性24例。将患者随机分为观察组和对照组（每组29例）。对照组患者接受依达拉奉治疗，观察组患者接受尿激肽原酶联合依达拉奉治疗。然后比较两组的临床疗效。结果显示，两组患者治疗后美国国立卫生研究院卒中量表评分及血清C反应蛋白水平均显著降低。观察组降低程度明显小于对照组，差异有统计学意义[（11.03±3.75）分 vs.（16.58±7.43）分，P<0.05；（9.88±4.82）mmol/L vs.（11.98±4.69）mmol/L，P<0.05]。两组患者治疗后血清血管内皮生长因子水平均显著升高。观察组升高程度明显高于对照组，差异有统计学意义[（268.51±77.34）ng/L vs.（188.82±57.33）ng/L，P<0.05]。观察组总有效率明显高于对照组，差异有统计学意义（89.66% vs. 62.07%，P<0.05）。综上所述，尿激肽原酶联合依达拉奉治疗大面积脑梗死有一定临床疗效。
